127 related articles for article (PubMed ID: 19880060)
1. 59-gene prognostic signature sub-stratifies high-risk neuroblastoma patients.
Vermeulen J; De Preter K; Laureys G; Speleman F; Vandesompele J
Lancet Oncol; 2009 Nov; 10(11):1030. PubMed ID: 19880060
[No Abstract] [Full Text] [Related]
2. IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma.
Bell JL; Turlapati R; Liu T; Schulte JH; Hüttelmaier S
J Clin Oncol; 2015 Apr; 33(11):1285-93. PubMed ID: 25753434
[TBL] [Abstract][Full Text] [Related]
3. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of MYCN and ID2 overexpression in neuroblastoma.
Alaminos M; Gerald WL; Cheung NK
Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351
[TBL] [Abstract][Full Text] [Related]
5. Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients.
van Wezel EM; Decarolis B; Stutterheim J; Zappeij-Kannegieter L; Berthold F; Schumacher-Kuckelkorn R; Simon T; Fiocco M; van Noesel MM; Caron HN; van der Schoot CE; Hero B; Tytgat GAM
Eur J Cancer; 2016 Feb; 54():149-158. PubMed ID: 26796600
[TBL] [Abstract][Full Text] [Related]
6. Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression.
Liu PY; Erriquez D; Marshall GM; Tee AE; Polly P; Wong M; Liu B; Bell JL; Zhang XD; Milazzo G; Cheung BB; Fox A; Swarbrick A; Hüttelmaier S; Kavallaris M; Perini G; Mattick JS; Dinger ME; Liu T
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24906397
[TBL] [Abstract][Full Text] [Related]
7. Genomic markers for neuroblastoma risk estimation: superseding tumor stage, age and MYCN?
Oberthuer A
Biomark Med; 2013 Dec; 7(6):905-8. PubMed ID: 24266822
[No Abstract] [Full Text] [Related]
8. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification.
Asgharzadeh S; Pique-Regi R; Sposto R; Wang H; Yang Y; Shimada H; Matthay K; Buckley J; Ortega A; Seeger RC
J Natl Cancer Inst; 2006 Sep; 98(17):1193-203. PubMed ID: 16954472
[TBL] [Abstract][Full Text] [Related]
9. Individual patient risk stratification of high-risk neuroblastomas using a two-gene score suited for clinical use.
von Stedingk K; De Preter K; Vandesompele J; Noguera R; Øra I; Koster J; Versteeg R; Påhlman S; Lindgren D; Axelson H
Int J Cancer; 2015 Aug; 137(4):868-77. PubMed ID: 25652004
[TBL] [Abstract][Full Text] [Related]
10. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma.
Alaminos M; Davalos V; Cheung NK; Gerald WL; Esteller M
J Natl Cancer Inst; 2004 Aug; 96(16):1208-19. PubMed ID: 15316056
[TBL] [Abstract][Full Text] [Related]
11. Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.
Oberthuer A; Juraeva D; Hero B; Volland R; Sterz C; Schmidt R; Faldum A; Kahlert Y; Engesser A; Asgharzadeh S; Seeger R; Ohira M; Nakagawara A; Scaruffi P; Tonini GP; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Vandesompele J; Speleman F; Noguera R; Piqueras M; Bénard J; Valent A; Avigad S; Yaniv I; Grundy RG; Ortmann M; Shao C; Schwab M; Eils R; Simon T; Theissen J; Berthold F; Westermann F; Brors B; Fischer M
Clin Cancer Res; 2015 Apr; 21(8):1904-15. PubMed ID: 25231397
[TBL] [Abstract][Full Text] [Related]
12. Risk-directed therapy and research in neuroblastoma.
Liu YL; Miser JS; Hsu WM
J Formos Med Assoc; 2014 Dec; 113(12):887-9. PubMed ID: 25499951
[No Abstract] [Full Text] [Related]
13. Long noncoding RNAs and neuroblastoma.
Pandey GK; Kanduri C
Oncotarget; 2015 Jul; 6(21):18265-75. PubMed ID: 26087192
[TBL] [Abstract][Full Text] [Related]
14. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling.
Schramm A; Schulte JH; Klein-Hitpass L; Havers W; Sieverts H; Berwanger B; Christiansen H; Warnat P; Brors B; Eils J; Eils R; Eggert A
Oncogene; 2005 Nov; 24(53):7902-12. PubMed ID: 16103881
[TBL] [Abstract][Full Text] [Related]
15. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
[TBL] [Abstract][Full Text] [Related]
16. RASSF1A methylation may have two biological roles in neuroblastoma tumorigenesis depending on the ploidy status and age of patients.
Haruta M; Kamijo T; Nakagawara A; Kaneko Y
Cancer Lett; 2014 Jun; 348(1-2):167-76. PubMed ID: 24680815
[TBL] [Abstract][Full Text] [Related]
17. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
[TBL] [Abstract][Full Text] [Related]
18. MYCN oncoprotein targets and their therapeutic potential.
Bell E; Chen L; Liu T; Marshall GM; Lunec J; Tweddle DA
Cancer Lett; 2010 Jul; 293(2):144-57. PubMed ID: 20153925
[TBL] [Abstract][Full Text] [Related]
19. Biological diagnosis for neuroblastoma using the combination of highly sensitive analysis of prognostic factors.
Tajiri T; Tanaka S; Higashi M; Kinoshita Y; Takahashi Y; Tatsuta K; Suita S
J Pediatr Surg; 2006 Mar; 41(3):560-6. PubMed ID: 16516635
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
